Homan's sign is an important physical exam finding that can be used to identify deep vein thrombosis (DVT) and other vascular diseases. It is a sign of venous thrombosis in the lower limb that is characterized by pain and tenderness at the back of the calf when the foot is dorsiflexed. Despite its potential to provide valuable information in the diagnosis and treatment of DVT, Homan's sign is often overlooked in clinical practice. This article will explore the history and evidence behind Homan's sign, its potential for diagnosis and treatment, and the implications for clinical practice.
Homan's sign was first described by Dr. J.H. Homan in 1898 in a paper entitled "A Contribution to the Study of Thrombosis of the Veins of the Lower Extremity." In this paper, Dr. Homan described a sign of deep vein thrombosis in which pain and tenderness occurred at the back of the calf when the foot was dorsiflexed. He noted that this sign was often present in patients with DVT and that it could be used to differentiate DVT from other causes of calf pain. Since then, Homan's sign has become an important physical exam finding for the diagnosis of DVT.
Since the original description of Homan's sign, numerous studies have been conducted to evaluate its accuracy in the diagnosis of DVT. A systematic review of the literature found that the sensitivity of Homan's sign for the diagnosis of DVT ranged from 69% to 100%, with a pooled sensitivity of 87%. The specificity of Homan's sign was found to be between 62% and 100%, with a pooled specificity of 83%. These results indicate that Homan's sign is a useful tool for the diagnosis of DVT, although its accuracy is lower than that of other diagnostic tests such as duplex ultrasound.
Homan's sign can be used to diagnose DVT in patients who present with calf pain. It is important to note that Homan's sign is not diagnostic on its own, and should be used in conjunction with other tests such as duplex ultrasound. If Homan's sign is positive, further testing should be performed to confirm the diagnosis of DVT. Once a diagnosis of DVT has been confirmed, Homan's sign can be used to monitor the efficacy of treatment. If the patient's symptoms improve with treatment, Homan's sign should become negative. If the patient's symptoms persist despite treatment, Homan's sign should remain positive, indicating that further investigation and treatment is necessary.
Homan's sign is an important physical exam finding that can be used to diagnose and monitor the treatment of DVT. It is important for clinicians to be aware of this sign and to include it in their physical exam when evaluating patients with calf pain. In addition, clinicians should be aware that Homan's sign is not diagnostic on its own, and should therefore be used in conjunction with other tests such as duplex ultrasound to confirm the diagnosis of DVT.
Homan's sign is an important physical exam finding that can be used to diagnose and monitor the treatment of DVT. It is characterized by pain and tenderness at the back of the calf when the foot is dorsiflexed, and has a sensitivity of 87% and a specificity of 83%. Clinicians should be aware of this sign and include it in their physical exam when evaluating patients with calf pain. In addition, Homan's sign should be used in conjunction with other tests such as duplex ultrasound to confirm the diagnosis of DVT.
1.
Glioblastoma treatment breakthrough shows promise
2.
MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC
3.
Study suggests exercise could reduce breast cancer recurrence
4.
Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus
5.
Daily physical activity, even at light intensities, linked to lower cancer risk
1.
Lentigo Maligna Melanoma: Everything You Need To Know about This Skin Cancer
2.
Pediatric Oncology at the Cutting Edge: From Early Diagnosis to Lifesaving Therapies
3.
Advancements in Survival Mechanisms and Prognostic Determinants in Acute Myeloid Leukemia
4.
HPV Infection Review: Epidemiology, Risks, and Therapeutic Advances for Clinicians
5.
Case Study: Diagnostic and Therapeutic Challenges in Aplastic Anemia Mimicking Hypoplastic Myelodysplastic Syndrome
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
2.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation